Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations

Lignende værker

• Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
  af: Zhang, Ping, et al.
  Udgivet: (2018)
• Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
  af: Yoshihito Kogure, et al.
  Udgivet: (2015-01-01)
• Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
  af: Kogure, Yoshihito, et al.
  Udgivet: (2015)
• The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
  af: Zhang, Qiuyi, et al.
  Udgivet: (2016)
• Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
  af: Chen, R.-L., et al.
  Udgivet: (2017)